Targeted therapeutics for severe refractory asthma: monoclonal antibodies. Issue 7 (2nd July 2016)

• Record Type: Journal Article
• Authors: Grainge, Christopher L.; Maltby, Steven; Gibson, Peter G.; Wark, Peter A. B.; McDonald, Vanessa M.
• Is Part Of: Expert review of clinical pharmacology. Volume 9:Issue 7(2016)
• Page Start: 927
• Page End: 941
• Publication Date: 2016-07-02
• Subjects: Severe asthma -- treatment-refractory asthma -- monoclonal -- phenotype -- biomarker -- targeted therapy -- multidimensional assessment; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1586/17512433.2016.1172208
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Severe asthma is a complex multifactorial disease that requires specialist multidisciplinary input for optimal clinical outcomes. Following multidimensional assessment for optimisation of current therapy, self-management skills and comorbidities, all patients should be accurately phenotyped. Only after this assessment has been completed should new monoclonal antibody therapies be considered. In this review, we summarise the new antibody approaches targeting identified pathological pathways in severe refractory asthma.